华特达因（000915.SZ）10月28日在投资者互动平台表示，公司及子公司目前没有您提到的长效胰岛素 类似物产品的研发和合作。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：子公司达因药业和"中国医学科学院药生所"战略合作协 议的主要方向和产品当中，有合作部分是长效胰岛素类似物产品，明年要进入临床？ ...

Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance [1] Financial Performance - The company achieved a revenue of 432,116,216.88 yuan in the third quarter of 2025, representing a year-on-year growth of 93.28% [1] - The net profit attributable to shareholders was 70,598,114.55 yuan, showing a year-on-year increase of 110.42% [1]

智通财经APP讯，华特达因(000915.SZ)发布2025年三季度报告，前三季度，公司实现营业收入16.03亿 元，同比增长16.30%。归属于上市公司股东的净利润4.08亿元，同比增长11.67%。归属于上市公司股东 的扣除非经常性损益的净利润4亿元，同比增长15.80%。 ...

Company Performance - Huate Dain reported Q3 performance with revenue of approximately 1.603 billion yuan, an increase of 16.3% year-on-year [1] - The net profit attributable to shareholders was about 408 million yuan, reflecting an increase of 11.67% year-on-year [1] - Basic earnings per share reached 1.7414 yuan, also up by 11.67% year-on-year [1] Market Context - As of the report, Huate Dain's market capitalization stands at 7.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2]

格隆汇10月24日丨华特达因(000915.SZ)公布2025年第三季度报告，营业收入为4.32亿元，同比上升 93.28%；归属于上市公司股东的净利润为7059.81万元，同比上升110.42%；归属于上市公司股东的扣除 非经常性损益的净利润为6734.60万元，同比上升153.51%。 ...

人民财讯10月24日电，华特达因（000915）10月24日披露2025年三季度报告，公司第三季度实现营业收 入4.32亿元，同比增长93.28%；归母净利润7059.81万元，同比增长110.42%。前三季度实现营业收入 16.03亿元，同比增长16.3%；归母净利润4.08亿元，同比增长11.67%。 ...

Financial Performance - For the first nine months of 2025, the company achieved operating revenue of CNY 1.603 billion, with a net profit attributable to shareholders of CNY 408 million, representing year-on-year growth of 16.30% and 11.67% respectively[4] - The pharmaceutical business generated operating revenue of CNY 1.578 billion and a net profit of CNY 757 million, reflecting increases of 16.77% and 9.64% compared to the same period in 2024[4] - In Q3 2025, the company reported operating revenue of CNY 432 million, a significant increase of 93.28% year-on-year, and a net profit of CNY 70.6 million, up 110.42% from the previous year[5] - The basic earnings per share for the first nine months of 2025 was CNY 1.7414, marking an increase of 11.67% compared to the same period last year[5] - Net profit for the period was ¥767,418,437.12, representing a 10.8% increase from ¥692,591,722.84 in the previous period[16] - Earnings per share (EPS) for the period was ¥1.7414, compared to ¥1.5594 in the prior period, reflecting a growth of 11.6%[16] Assets and Liabilities - The company's total assets as of September 30, 2025, were CNY 4.780 billion, a decrease of 3.06% from the end of the previous year[5] - The company's total current assets amount to ¥3,372,578,876.81, a decrease from ¥3,510,737,250.04 at the beginning of the period[12] - The total assets of the company are ¥4,779,984,839.06, down from ¥4,930,936,591.73[13] - The company's total liabilities amount to ¥473,747,067.84, an increase from ¥418,011,480.27[13] - Total liabilities increased to ¥573,205,007.48 from ¥518,499,753.28, indicating a rise of 10.6%[14] - The company's equity attributable to shareholders decreased by 2.08% to CNY 2.851 billion compared to the end of the previous year[5] - Total equity attributable to shareholders decreased to ¥2,851,053,959.18 from ¥2,911,651,440.88, a decline of 2.1%[14] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 955 million, representing a 70.50% increase year-on-year[5] - The net cash flow from operating activities was CNY 954,987,097.75, an increase of 70.4% compared to CNY 560,093,957.28 in the previous period[18] - Total cash inflow from operating activities amounted to CNY 2,654,451,852.64, up from CNY 2,015,317,935.16, reflecting a growth of 31.6%[18] - Cash outflow from operating activities was CNY 1,699,464,754.89, compared to CNY 1,455,223,977.88, representing an increase of 16.8%[18] - The ending balance of cash and cash equivalents was CNY 1,820,357,317.28, an increase from CNY 1,610,259,774.32[18] Expenses - Sales expenses for the first nine months of 2025 amounted to CNY 342.8 million, a rise of 37.13% compared to the same period in 2024, attributed to higher marketing activity costs and sales personnel bonuses[9] - The company experienced a 2118.27% increase in credit impairment losses, amounting to CNY 6.6 million, mainly due to the recovery of large overdue accounts[9] - Research and development expenses were ¥68,738,075.33, slightly up from ¥64,281,936.19 in the prior period[15] - The company recorded a tax expense of ¥131,540,958.88, which is marginally higher than ¥129,753,178.59 in the previous period[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,598[10] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[10] - The company has no preferred shareholders as indicated in the report[12] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 262.65% to CNY 203.7 million, primarily due to increased advance payments from customers[8] - The company reported a financial asset fair value change gain of ¥8,168,115.06, compared to ¥6,090,195.26 in the previous period[16] - Cash inflow from investment activities totaled CNY 2,012,895,539.01, down from CNY 2,186,690,952.50, indicating a decrease of 7.9%[18] - Cash outflow from investment activities increased to CNY 2,234,199,712.60 from CNY 2,081,136,231.58, marking a rise of 7.4%[18] - Cash flow from financing activities resulted in a net outflow of CNY -973,075,444.00, compared to CNY -1,090,241,186.50 previously[18]

Core Insights - The company reported a third-quarter revenue of 432 million, representing a year-over-year increase of 93.28% [1] - The net profit for the third quarter was 70.6 million, showing a year-over-year growth of 110.42% [1] - For the first three quarters, the total revenue reached 1.603 billion, with a year-over-year increase of 16.30% [1] - The net profit for the first three quarters was 408 million, reflecting a year-over-year growth of 11.67% [1]

山东华特达因健康股份有限公司 董事会薪酬与考核委员会工作规则 第一章 总则 第一条 为进一步建立健全公司董事(非独立董事)及高级管理人员的考核和 薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》《上市公司 治理准则》《上市公司独立董事管理办法》《公司章程》等规定，制定本工作规 则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要负责制定公司董事及高级管理人员的考核标准并进行考核，负责制定、审查 公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本规则所称董事是指在本公司领取薪酬的董事长、董事，高级管理 人员是指董事会聘任的总经理、财务总监、副总经理、董事会秘书及由总经理 提请董事会聘任的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，其中独立董事二名。 第五条 薪酬与考核委员会委员由董事长、过半数独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事担任，主任委员由 董事长提名，经董事会选举产生。 第七条 薪酬与考核委员会任期与董事会任期一致，委员任期届满，连选可 以连任。 ...

董事会提名委员会工作规则 第一章 总 则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董事管理 办法》《公司章程》及其他有关规定，公司特设立董事会提名委员会，并制定本 工作规则。 第二条 董事会提名委员会是董事会按照股东会决议设立的专门工作机构， 主要负责董事、高级管理人员的人选、选择标准、程序等事项向董事会提出建议。 第二章 人员组成 第三条 提名委员会成员为 3 人，由董事长和 2 名独立董事组成。 山东华特达因健康股份有限公司 第四条 提名委员会委员由董事长、过半数独立董事或者全体董事的三分之 一提名并由董事会选举产生。 第五条 提名委员会设主任委员 1 名，由独立董事委员担任，由董事长提名， 经董事会选举产生。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，则自动失去委员资格，并由董事会根据上 述规定补足委员人数。 第七条 股东关系管理部协助董事会秘书处理提名委员会的日常事务，包括 日常工作联络和提名委员会会议的组织筹备等。 第三章 职责权限 第八条 公司董 ...